![]() |
PTSE® 12/36
|
![]() |
PTSE® 20/40 |
PHARMACUETICAL |
The Americas:Paul Nardone Fax: 201.343.0608
The rest of the World:Jane Schwarz |
![]() | |
Challenge | HME Solution |
• Low bioavailability due to poor API solubility | • Rapid and cost-effective method for solubility enhancement of poorly soluble APIs (continuous, no drying step is needed |
• Stability issues (moisture sensitive API) | • Dry process suitable for moisture sensitive drugs |
• Unpleasant taste of API | • Taste masking of poorly tasting APIs through HME |
• Non-robust prolonged release properties | • Easy, reliable way to achieve prolonged drug release • Reduced risk of dose dumping compared to coated monolithic systems • No solvents (safety, cost and time-saving as no subsequent drying is needed) |
• Formulation of API as films | • HME as a rapid and reliable method for preparation of films (strips or patches) |
![]() |
• Continuous process (time and cost saving, better controllability) against batch processes |
• Well established technology (wide spectrum of excipients commercially available and high level of expertise is already established) |
• Highly reproducible process (batch uniformity and conformity) |
• Flexible process (monolithic and multiparticulate dosage forms can be obtained) |
• Easy, time and cost saving way to modify drug release properties (solubility enhancement or release prolongation) |
AAPS 2014 Annual |
San Diego, CA | Nov. 2 - 6, 2014 |
We appreciate your interest and will immediately reply to your questions and requests.
All software downloads must be purchased prior to clicking below by contacting the C.W. Brabender® parts dept.